Madrid, Spain

ESMO (European Society for Medical Oncology) Congress 2020

  • Start Date:

    14 Sep, 2020

  • End Date:

    29 Sep, 2020

  • Location:

    Virtual Conference


POSTER PRESENTATIONS

1

Poster #1322P REAL-WORLD TREATMENT PATTERNS AND IMMUNOTHERAPY (IO) SEQUENCING BASED ON PD-L1 TPS IN EUROPEAN PATIENTS WITH METASTATIC NSCLC

Speakers: Janowicz E, Ognar RG, Capart P, Stoyanov N, Nguyen B, Combest A, Anderson DJC
Date: Thursday, September 17, 2020

2

Poster #1340P REAL-WORLD TREATMENT PATTERNS AND OUTCOMES IN PATIENTS WITH ADVANCED, ALK + NON-SMALL CELL LUNG CANCER (NSCLC) IN EUROPE

Speakers: Stoyanov N, Combest A, Nguyen B, Ognar R, Reitsma D, Capart P, Anderson DJC
Date: Thursday, September 17, 2020

3

Poster #627P REAL-WORLD EVIDENCE (RWE) FOR PATIENTS (PTS) WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) TREATED WITH CABAZITAXEL (CBZ): COMPARISON WITH THE RANDOMIZED CLINICAL STUDY CARD

Speakers: de Wit R, Feedland S, Oudard S, Marinov G, Capart P, Combest A, Peterson R, Ozatilgan A, Morgans A
Date: Thursday, September 17, 2020

PPD WEBINAR

Advancing Early Stage Oncology Research with Adaptive Designs and Master Protocols

Date: Tuesday, September 29, 2020 | 10:00 am EDT

Speakers:

  • Jurgen Hummel, MSc, Senior Director of Statistical Science, Biostatistics, PPD
  • Dirk Reitsma, MD, Vice President and Therapeutic Area Head, Oncology, Global Product Development, PPD

To be discussed:

  • Improved determination of the maximum tolerated dose, comparing different designs for dose selection
  • Advantages of basket trial design for finding the most appropriate indication(s)
  • Current regulatory positions and outlook of the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human use (ICH)
  • Operational implications of different designs